Recently, the coordinated mono-allelic loss of BRCA2/RB1 on 13q was shown to evoke aggressive phenotypes in prostatic adenocarcinomas vulnerable to PARP inhibitor-based therapy [21]. This evidence concerns the gene RB1 and prostate adenocarcinoma.